Likewise, inhibition of pro-inflammatory cytokines, particularly IL-6 (for example, via monoclonal antibody therapy in CKD patients), has been proposed as a strategy to attenuate the vicious cycle linking stress hormones and systemic inflammation [60,61]. The gene discussed is IL6; the disease is chronic kidney disease.